Photo of Hensin Tsao,  MD, PhD

Hensin Tsao, MD, PhD

Massachusetts General Hospital

Massachusetts General Hospital

Hensin Tsao, MD, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Dermatology, Harvard Medical School
  • Director, MGH Melanoma and Pigmented Lesion Center, Dermatology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our laboratory is interested in the genetic determinants of cutaneous melanoma. We have developed and maintain a registry of familial melanoma patients in order to better understand the genetic loci and mechanisms that contribute to inherited melanoma predisposition. We also have an interest in molecules that participate in the repair of DNA in response to ultraviolet damage.

Publications

Powered by Harvard Catalyst
  • Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, Jönsson G, Frederick DT, Tsao H. BAP1 Has a Survival Role in Cutaneous Melanoma. J Invest Dermatol 2015; 135:1089-97. PubMed
  • Luo S, Lobo AZ, Tanabe KK, Muzikansky A, Durazzo T, Sober A, Tsao H, Cosimi AB, Lawrence DP, Duncan LM. Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surg 2015. PubMed
  • Tsao H, Olazagasti JM, Cordoro KM, Brewer JD, Taylor SC, Bordeaux JS, Chren MM, Sober AJ, Tegeler C, Bhushan R, Begolka WS. Early detection of melanoma: Reviewing the ABCDEs. J Am Acad Dermatol 2015; 72:717-23. PubMed
  • Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol 2015. PubMed
  • Paraiso KH, Thakur MD, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype. 2015; 5:264-73. PubMed
  • Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. 2015; 5:274-87. PubMed
  • Roh MR, Eliades P, Gupta S, Tsao H. Cutaneous Melanoma in Women. Int J Womens Dermatol 2015; 1:21-25. PubMed
  • Yonekawa Y, Kim IK, Gragoudas ES, Njauw CN, Tsao H, Jakobiec FA, Stacy RC. Aggressive skull base metastasis from uveal melanoma: a clinicopathologic study. Eur J Ophthalmol 2014. PubMed
  • Miller DM, Flaherty KT, Tsao H. Commentary: Molecular testing in melanoma. J Am Acad Dermatol 2014; 70:863-70. PubMed
  • Redmond RW, Rajadurai A, Udayakumar D, Sviderskaya EV, Tsao H. Melanocytes are selectively vulnerable to UVA-mediated bystander oxidative signaling. J Invest Dermatol 2014; 134:1083-90. PubMed
  • Marzuka-Alcalá A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. Methods Mol Biol 2013; 1102:381-93. PubMed
  • Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 2013; 19:4383-91. PubMed
  • Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma. Mol Cancer Ther 2013. PubMed
  • Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013; 50:264-70. PubMed
  • Chen ST, Geller AC, Tsao H. Update on the Epidemiology of Melanoma. Curr Dermatol Rep 2013; 2:24-34. PubMed
  • Lobo AZ, Tanabe KK, Luo S, Muzikansky A, Sober AJ, Tsao H, Cosimi AB, Duncan LM. The distribution of microscopic melanoma metastases in sentinel lymph nodes: implications for pathology protocols. Am J Surg Pathol 2012; 36:1841-8. PubMed
  • Hawryluk EB, Sober AJ, Piris A, Nazarian RM, Hoang MP, Tsao H, Mihm MC, Duncan LM. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol 2012; 67:727-35. PubMed
  • Hung T, Piris A, Lobo A, Mihm MC, Sober AJ, Tsao H, Tanabe KK, Duncan LM. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol 2012. PubMed
  • Harbst K, Staaf J, Lauss M, Karlsson A, Måsbäck A, Johansson I, Bendahl PO, Vallon-Christersson J, Törngren T, Ekedahl H, Geisler J, Höglund M, Ringnér M, Lundgren L, Jirström K, Olsson H, Ingvar C, Borg Å, Tsao H, Jönsson G. Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res 2012; 18:4026-36. PubMed
  • Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55. PubMed
  • Lipworth AD, Park JM, Trefrey BL, Rubin KM, Geller AC, Sober AJ, Tsao H. Urgent access to a specialty care melanoma clinic is associated with a higher rate of melanoma detection. J Am Acad Dermatol 2011. PubMed
  • Luo S, Chaplin AC, Langley RG, Njauw CN, Duncan LM, Miller RA, Tsao H. Agminated segmental nevi demonstrating intranevic concordance of BRAF status. J Invest Dermatol 2011; 131:788-90. PubMed
  • Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, Puig S, Gruis NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, Hogg D, Tsao H. A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds. J Invest Dermatol 2011; 131:480-6. PubMed
  • Ko JM, Velez NF, Tsao H. Pathways to melanoma. 2011; 29:210-7. PubMed
  • Tsao H, Tanabe KK, Lawrence DP, Piris A. Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion. N Engl J Med 2010; 363:1352-60. PubMed
  • Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. 2010; 29:190-5. PubMed
  • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9. PubMed
  • Feramisco JD, Tsao H, Siegel DH. Genetics for the Practicing Dermatologist. 2010; 29:127-136. PubMed
  • Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med 2010; 31:194-204. PubMed
  • Sober AJ, Tsao H. Martin C. Mihm, Jr and the history of the Pigmented Lesion Clinic at the Massachusetts General Hospital. J Cutan Pathol 2010; 37 Suppl 1:8-11. PubMed
  • Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 2010; 70:552-9. PubMed
  • Yang G, Thieu K, Tsai KY, Piris A, Udayakumar D, Njauw CN, Ramoni MF, Tsao H. Dynamic gene expression analysis links melanocyte growth arrest with nevogenesis. Cancer Res 2009; 69:9029-37. PubMed
  • Sadreyev RI, Feramisco JD, Tsao H, Grishin NV. Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways. Bioinformatics 2009; 25:2891-6. PubMed
  • Feramisco JD, Sadreyev RI, Murray ML, Grishin NV, Tsao H. Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol 2009; 129:2628-36. PubMed
  • Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009; 61:677.e1-14. PubMed
  • Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol 2009; 61:88-93. PubMed
  • Udayakumar D,Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am 2009; 23:415-29, vii. PubMed
  • Nelson AA,Tsao H. Melanoma and genetics. Clin Dermatol 2008; 27:46-52. PubMed
  • Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med 2009; 1:95. PubMed
  • Sun BK,Tsao H. X-chromosome inactivation and skin disease. J Invest Dermatol 2008; 128:2753-9. PubMed
  • Sun BK,Tsao H. Small RNAs in development and disease. J Am Acad Dermatol 2009; 59:725-37; quiz 738-40. PubMed
  • Hocker TL,Singh MK,Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008; 128:2575-95. PubMed
  • Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, Ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT, Newton Bishop J. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008; 44:1269-74. PubMed
  • Friedman RJ, Gutkowicz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, Mihm MC Jr, Googe P, King R, Prieto VG, Kopf AW, Polsky D, Rabinovitz H, Oliviero M, Cognetta A, Rigel DS, Marghoob A, Rivers J, Johr R, Grant-Kels JM, Tsao H. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008; 144:476-82. PubMed
  • Zhang G, Njauw CN, Park JM, Naruse C, Asano M, Tsao H. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008; 68:1691-6. PubMed
  • Park JM, Tsao H, Tsao S. Combined use of intense pulsed light and Q-switched ruby laser for complex dyspigmentation among Asian patients. Lasers Surg Med 2008; 40:128-33. PubMed
  • Feramisco JD, Casey RL, Tsao H. Recent updates on genetics: teaching old dogmas new tricks. Pediatr Dermatol 2008; 25:99-108. PubMed
  • Somoano B, Tsao H. Genodermatoses with cutaneous tumors and internal malignancies. Dermatol Clin 2007; 26:69-87, viii. PubMed
  • McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007; 104:19936-41. PubMed
  • Tsao H, Florez JC. Introduction to genetic association studies. J Invest Dermatol 2007; 127:2283-7. PubMed
  • Yang G, Curley D, Bosenberg MW, Tsao H. Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res 2007; 67:5649-57. PubMed
  • Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007; 28:578-88. PubMed
  • Tsai KY, Tsao H. Primer on the human genome. J Am Acad Dermatol 2007; 56:719-35. PubMed
  • Lang J, Hayward N, Goldgar D, Tsao H, Hogg D, Palmer J, Stark M, Tobias ES, MacKie R. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer 2006; 46:277-87. PubMed
  • Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2006; 44:99-106. PubMed
  • Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. J Invest Dermatol 2006; 126:2490-506. PubMed
  • Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66:9818-28. PubMed
  • Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 2005; 43:501-6. PubMed
  • Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12:2301s-2307s. PubMed
  • Stratigos AJ, Yang G, Dimisianos R, Nicolaou V, Stefanaki I, Katsambas AD, Tsao H. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol 2005; 126:399-401. PubMed
  • Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006; 19:1-8. PubMed
  • Goggins W, Daniels GH, Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 2005; 118:185-8. PubMed
  • Tsao H. The SNPs of RAF. J Invest Dermatol 2005; 125:xiv-xv. PubMed
  • Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005; 125:1242-51. PubMed
  • Tsao H, Sober AJ, Niendorf KB, Zembowicz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 2004; 350:924-32. PubMed
  • Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-41. PubMed
  • Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004; 140:67-70. PubMed
  • Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139:1620-4; discussion 1624. PubMed
  • Tsao H, Mihm MC, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003; 49:865-72. PubMed
  • Bevona C, Tannous Z, Tsao H. Dermal melanocytic proliferation with features of a plaque-type blue nevus and neurocristic hamartoma. J Am Acad Dermatol 2003; 49:924-9. PubMed
  • Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139:282-8. PubMed
  • Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639-43. PubMed
  • Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catrical. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22:5157-72. PubMed
  • Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138:799-802. PubMed
  • Tsao H, Kwitkiwski K, Sober AJ. A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. J Am Acad Dermatol 2002; 46:55-61. PubMed
  • Tsao H. Genetics of nonmelanoma skin cancer. Arch Dermatol 2001; 137:1486-92. PubMed
  • Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001; 137:325-30. PubMed
  • Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 2001; 91:874-80. PubMed
  • Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136:1118-22. PubMed
  • Tsao H, Lerner LH. Pigmented purpuric eruption associated with injection medroxyprogesterone acetate. J Am Acad Dermatol 2000; 43:308-10. PubMed
  • Tsao H. Update on familial cancer syndromes and the skin. J Am Acad Dermatol 2000; 42:939-69; quiz 970-2. PubMed
  • Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 2000; 6:139-45. PubMed
  • Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000; 60:1800-4. PubMed
  • Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol 2013; 31:148-55. PubMed
  • Tsao H. American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Targets of genetic injury in cutaneous melanoma. J Am Acad Dermatol 1999; 41:459-61. PubMed
  • Tsao H, Sober AJ, Rogers GS. Reply J Am Acad Dermatol 1999; 41:282-3. PubMed
  • Tsao H, Tahan SR. Images in clinical medicine. Keratoacanthoma. N Engl J Med 1999; 340:708. PubMed
  • Tsao H, Zhang X, Majewski P, Haluska FG. Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res 1999; 59:172-4. PubMed
  • Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res 1998; 58:109-13. PubMed
Hide